Comparing acetazolamide and dapagliflozin for treating acute heart failure
Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients
This study is testing whether adding acetazolamide or dapagliflozin to standard treatment can help adults with acute heart failure feel better and manage fluid overload.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Helwan University Academic / other |
| Locations | 1 site (Cairo) |
| Trial ID | NCT06535529 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the effectiveness of acetazolamide versus dapagliflozin as an add-on treatment for adult patients experiencing acute decompensated heart failure (ADHF) with signs of volume overload. Participants will receive either drug alongside standard intravenous loop diuretics for three days, and the study will measure outcomes such as reductions in NT-proBNP levels and loop diuretic efficiency. The trial is designed as a prospective, open-label, randomized, two-armed parallel comparator study conducted at Cairo University Hospitals.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with acute decompensated heart failure and clinical signs of volume overload.
Not a fit: Patients with an estimated glomerular filtration rate below 20 mL/min/1.73 m2 or those on maintenance therapy with acetazolamide or SGLT2 inhibitors may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a more effective treatment option for patients with acute decompensated heart failure.
How similar studies have performed: While the specific combination of acetazolamide and dapagliflozin has not been extensively tested, both drugs have shown promise in managing heart failure in other studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female patients of 18 years of age or older. * An elective or emergency hospital admission with clinical diagnosis of decompensated HF with at least one clinical sign of volume overload (e.g. edema, ascites confirmed by echography or pleural effusion confirmed by chest X-ray or echography). * Assessed LVEF by any imaging technique; i.e. echocardiography, catheterization, nuclear scan magnetic resonance imaging within 12 months of inclusion. Exclusion Criteria: * The receipt of acetazolamide maintenance therapy. * Receipt of an SGLT2 inhibitor in the 48 hours before randomization. * An estimated glomerular filtration rate (eGFR) \<20 mL/min/1.73 m2. * Use of any non-protocol defined diuretic agent with the exception of mineralocorticoid receptor antagonists during the treatment phase of the study. Thiazides, metolazone, indapamide and amiloride should be stopped upon study inclusion. If patient is taking a combination drug including a thiazide-type diuretic, the thiazide-type diuretic should be stopped.
Where this trial is running
Cairo
- Critical Care Medicine Department - Cairo University Hospitals. — Cairo, Egypt (Recruiting)
Study contacts
- Study coordinator: Nouran Mo Anwar, Bachelor
- Email: Nouran.Anwar@pharm.helwan.edu.eg
- Phone: 01124119559
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.